Image Description (Description)
Chemical structure of oxaliplatin showing the platinum (Pt) atom coordinated with amine groups and oxalate ligands.*
Oxaliplatin Injection, Solution
Product Images NDC 42677-336
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 42677-336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Shandong New Time Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image Description (Figure1)
A survival analysis Kaplan-Meier curve comparing Disease-Free Survival (DFS) probability over months for two treatment arms: FOLFOX4 and LV5FU2. The chart includes a legend with number of events and percentages for each arm, hazard ratio with confidence interval, stratified logrank test p-value, and a table of patients at risk over time for both arms.*
Image Description (Figure2)
A Kaplan-Meier survival curve graph displaying disease-free survival (DFS) probability over time in months. The chart compares two treatment arms: FOLFOX4 and LV5FU2, labeled at the bottom. The graph includes statistical data with a hazard ratio of 0.78 and a p-value of 0.005 for Stage III. The y-axis represents DFS probability from 0 to 1.0, and the x-axis represents DFS duration up to 72 months.*
Image Description (Figure3)
A survival curve chart comparing the median survival of patients treated with Oxaliplatin Injection USP combined with 5-FU/LV, Oxaliplatin Injection USP combined with irinotecan, and irinotecan combined with 5-FU/LV over 24 months. The vertical axis shows the percentage of patients surviving, and the horizontal axis shows time in months. The chart includes median survival times for each treatment regimen and a statistical significance note (p < 0.0001).*
Image Description (Carton 100mg)
Packaging label for Oxaliplatin Injection, USP, 100 mg/20 mL (5 mg/mL) intravenous injection solution. The label indicates it is a cytotoxic agent for intravenous infusion after dilution, requiring gloves when handling. Manufactured by Shandong New Time Pharmaceutical Co., Ltd. The label includes storage instructions, warnings, and a barcode.*
Image Description (Carton 50mg)
Packaging label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) solution for intravenous infusion. The label includes warnings about cytotoxicity and instructions not to mix with sodium chloride/chloride-containing solutions. It lists Shandong New Time Pharmaceutical Co., Ltd. as the manufacturer and provides storage instructions and handling precautions.*
Image Description (Container 100mg)
Label for Oxaliplatin Injection, USP, 100 mg/20 mL (5 mg/mL) solution for intravenous infusion. The label includes usage warnings, storage instructions, and manufacturer details for Shandong New Time Pharmaceutical Co., Ltd. The label also displays a barcode, lot, and expiration placeholders.*
Image Description (Container50mg)
Label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) intravenous solution. The label includes warnings about cytotoxicity and advises against mixing with sodium chloride or chloride-containing solutions. It identifies the product as a single-dose vial from Shandong New Time Pharmaceutical Co., Ltd., with storage instructions and barcode visible.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
